key: cord-0797568-9h2nqd5g authors: He, Shan; Granot‐Hershkovitz, Einat; Zhang, Ying; Bressler, Jan; Tarraf, Wassim; Yu, Bing; Huang, Tianyi; Zeng, Donglin; Wassertheil‐Smoller, Sylvia; Lamar, Melissa; Daviglus, Martha; Marquine, Maria J.; Cai, Jianwen; Mosley, Thomas; Kaplan, Robert; Boerwinkle, Eric; Fornage, Myriam; DeCarli, Charles; Kristal, Bruce; Gonzalez, Hector M.; Sofer, Tamar title: Blood metabolites predicting mild cognitive impairment in the study of Latinos‐investigation of neurocognitive aging (HCHS/SOL) date: 2022-02-23 journal: Alzheimers Dement (Amst) DOI: 10.1002/dad2.12259 sha: 12e2de7978a62d4c7e117371e7f873497ccd5742 doc_id: 797568 cord_uid: 9h2nqd5g INTRODUCTION: Blood metabolomics‐based biomarkers may be useful to predict measures of neurocognitive aging. METHODS: We tested the association between 707 blood metabolites measured in 1451 participants from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL), with mild cognitive impairment (MCI) and global cognitive change assessed 7 years later. We further used Lasso penalized regression to construct a metabolomics risk score (MRS) that predicts MCI, potentially identifying a different set of metabolites than those discovered in individual‐metabolite analysis. RESULTS: We identified 20 metabolites predicting prevalent MCI and/or global cognitive change. Six of them were novel and 14 were previously reported as associated with neurocognitive aging outcomes. The MCI MRS comprised 61 metabolites and improved prediction accuracy from 84% (minimally adjusted model) to 89% in the entire dataset and from 75% to 87% among apolipoprotein E ε4 carriers. DISCUSSION: Blood metabolites may serve as biomarkers identifying individuals at risk for MCI among US Hispanics/Latinos. Hispanics/Latinos in the United States are at higher risk for mild cognitive impairment (MCI) and Alzheimer's disease and related dementias (ADRD), compared to non-Hispanic Whites, and are a rapidly growing ethnic population in the United States. 1 Various risk factors may explain the rate differences between populations, including genetic susceptibility, health conditions, lifestyle, and environmental factors. 2 For example, cardiovascular disease and diabetes are more prevalent in Hispanics/Latinos compared to non-Hispanic Whites and are known to increase the risk for ADRD. On the other hand, the strongest known genetic risk factor for ADRD, apolipoprotein E (APOE) ε4, demonstrates a weaker association in Hispanics/Latinos, compared to other populations. 3 MCI is the stage between the expected cognitive decline of normal aging and the development of dementia, 4 although some individuals with MCI may revert to normal. 5 Individuals diagnosed with MCI experience mild changes in thinking, memory, language, and/or judgment abilities greater than age-related expected changes. MCI can result from a variety of etiologies, some of which are reversible, and are affected by medications, injuries, sleep, exercise, education, and diet. 6 These MCI risk factors may lead to metabolic dysregulation. In the last decade, metabolome assessment has emerged as a new approach for biomarker discovery, and for evaluating the progress of disease and its underlying pathophysiology. 7 Recent studies have demonstrated risk prediction of MCI and ADRD based on blood metabolite biomarkers in prospective studies. 8, 9 For example, higher plasma anthranilic acid levels were associated with a greater risk of dementia in the Framingham Offspring Study. 10 Thus, metabolome screening in middle-aged adults can detect plausible biomarkers that may improve risk prediction for MCI and can facilitate modifiable interventions at earlier stages of the disease. 11, 12 However, most studies were conducted in non-Hispanic US populations, 8 and metabolite associations may not generalize between populations. In one study, 10 prospectively predictive phospholipids metabolites for MCI or dementia found in non-Hispanic Whites failed replication in a Black cohort. 13 Another study in European Americans 12 replicated only one (out of seven) prospective predictive metabolite for dementia previously found in Blacks. Given the differences in risk factors and rates of cognitive decline and MCI across populations, we hypothesized that optimal metabolomics biomarkers in Hispanics/Latinos may differ from those in other populations. We examined the associations of blood metabolites with MCI and global cognitive change over an average 7-year follow-up period among middle-aged and older adults in the Study of Latinos-Investigation of Neurocognitive Aging (SOL-INCA). 14 SOL-INCA is an ancillary study to the Hispanic Community Health Study/Study of Latinos (HCHS/SOL). The analysis steps are described in Figure 1 . We hypothesized that there are metabolites associated with MCI and cognitive decline in Hispanics/Latinos. We first tested the association of 707 metabolites with MCI and global cognitive change (Step A). We assessed the single-metabolite associations based on previous literature (Step B) and generalization to Europeans and Blacks from the Atherosclerosis Risk in Communities (ARIC) study using a proxy-trait approach by testing metabolite associations with change in cognitive tests ( Step C). Next, we used a Lasso regression to construct a metabolite risk score (MRS, Step D). An MRS is a combined metabolomics measure, integrating information across multiple metabolites at once. Therefore, an MRS can potentially serve as a better biomarker of the metabolic environment related to a specific outcome compared to individual metabolites. Finally, we also explored whether previously reported metabolite associations with cognitive function generalize to the Hispanics/Latinos in the SOL-INCA target population ( Step E). The HCHS/SOL is a US population-based longitudinal cohort study with 16 All study participants provided written informed consent in their preferred language (Spanish/English) to use their genetic and nongenetic data. The study was reviewed and approved by the institutional review boards at all collaborating institutions. We studied two primary neurocognitive outcomes: MCI at the SOL- ations were used for the analysis in Figure 1 , Step C, as described later. Metabolites were measured in serum of blood drawn after at least unidentified. 23 Further details on metabolites' quality control are provided in Figure S1 in supporting information. Overall, we tested 707 metabolites in this study. Step (A), association analysis between single metabolites and neurocognitive outcomes. Step (B), review of previous literature reporting the metabolites with false discovery rate (FDR)-significant associations. Step (C), generalization of the FDR-significant metabolite associations in the Atherosclerosis Risk in Communities (ARIC) dataset. Step (D), construction of a metabolite risk score (MRS) for neurocognitive outcomes. Step (E), generalization of previously reported metabolite-neurocognitive associations in SOL-INCA We characterized the target population that the sample represents We tested the associations of each metabolite with each of the neurocognitive outcomes accounting for the complex survey design of the data using the R "survey" package, 24 with a "quasi-Poisson" family for a binary outcome (Figure 1, Step A). We used three nested regres- We also stratified models 1 and 2 by APOE ɛ4 allele carrier status. The significance threshold was false discovery rate (FDR) adjusted Pvalue < .05 (q-value) computed in each analysis separately. Biological pathways for metabolites were provided by Metabolon's annotation file. Step B). We evaluated the generalizability of the discovered metabolite associations in the ARIC study ( Figure 1, Step C). ARIC is a longitudinal cohort study with cognitive measures and metabolite profiling based on a similar Metabolon platform. ARIC did not have equivalent measures of MCI and global cognitive change; therefore, we used a proxy-generalization approach testing the metabolites' associations with change in cognitive test results. Further details are provided in the supporting information. We performed Lasso-penalized regression to optimally select and estimate the joint effect of multiple metabolites that together predict MCI in the HCHS/SOL analytic sample (Step D in Figure 1 ). 25 Based on the selected metabolites and their estimated effects, we constructed an MRS for MCI. Further details are provided in the supporting information. We identified two manuscripts reporting associations of metabolites with MCI and AD, using a similar Metabolon platform. 12, 26 To study whether their reported associations generalize to associations with MCI and global cognitive change in Hispanics/Latinos, we inspected the metabolites they reported in our single-metabolite association analyses ( Figure 1 , Step E). Data availability HCHS/SOL and SOL-INCA data can be obtained from dbGaP under accession number phs000810.v1.p1. Summary statistics from association analyses of all metabolites and all studied phenotypes are available in a GitHub repository. In addition, code for constructing the MCI MRS based on the Lasso-selected metabolites is provided in the same GitHub repository. We performed metabolite association analysis across the total analytic sample and stratified by APOE ε4 carrier status. Table 2 summarizes the associations that passed the FDR-adjusted threshold in any one of the three nested regression models. Table S1 in supporting information provides annotations for these metabolites. Across the three regres-sion models, we identified 13 metabolites associated with MCI and 8 metabolites associated with global cognitive change. Effect directions persisted across the three models for all associations (data not shown). One metabolite, quinolinate, was associated with both MCI and global cognitive change. Results from complete-cases metabolite analyses were similar to the analyses of the imputed metabolites. All but three associations were identified in one of the APOE ε4 stratification groups (carriers or non-carriers), with most lipid metabolites identified in the APOE ε4 non-carrier group. Figure 2 visualizes the correlations between the metabolites predicting MCI and/or global cognitive change as outlined in Table 2 . Table 3 Tables S2-S5 in supporting information summarize proxy-phenotype selection for the ARIC cohort generalization study as described in the supporting information. Out of the 20 associated metabolites with either MCI or global cognitive change in our analytic dataset, 11 were available for ARIC generalization tests. Table S6 in supporting information summarizes the results from the generalization study in ARIC stratified by race: European American and Black. One association was generalized; 7-methylguanine was associated with improved cognitive change in the total analytic sample was associated with improved DSS change in Black ARIC APOE ε4 carriers and non-carriers. We performed Lasso regression to jointly select metabolites associated with MCI and estimate their effects. Sixty-one metabolites were selected by the algorithm and formed an MRS. Thymol treatment is associated with enhanced cognitive activity in rat models of dementia. Notes: In a case where an association was discovered in both the combined cohort and one of the strata (i.e., methylguanine, kynurenine, and quinolinate), we report the direction in the combined cohort. (Figure 1, Step E) There were 13 metabolites associated with MCI after FDR control in our analysis. Of these, eight were lipids, and seven of them were identified in APOE ε4 non-carriers (Table 2 ). As outlined in Table 3 , five of the eight lipids were previously reported as associated with neurocognitive phenotypes with similar directions of associations (glycolithocholic acid 3-sulfate, glycodeoxycholatesulfate, 1-palmitoleoyl-GPC [16:1], 3-hydroxy-3-methylglutarate, and 9,10-DiHOME). The single lipid association detected in APOE ε4 carriers was with 3-hydroxy-3-methylglutarate previously reported as a risk-decreasing factor for AD. 27 Lipids are known for their crucial function in cell signaling, physiological processes, and disease pathology, especially in the brain. 28 APOE ε4 genotype is known to disrupt lipid transport and metabolism in AD. Our results from the APOE ε4 non-carriers emphasize the importance of lipids dysregulation in neurocognitive phenotypes, even in the absence of the APOE ε4 allele. 28 Isocitrate is another metabolite associated with increased MCI risk in APOE ε4 carriers. It was previously reported as having a higher concentration in serum of AD patients compared to cognitively normal older adults. 29 Isocitrate is a part of the citrate cycle pathway, responsible for the oxidation of carbohydrates and fatty acids. We identified eight metabolites associated with global cognitive change; all were previously implicated with neurocognitive pheno-types ( Table 3 ). The directions of six of the associations were inconsistent with the literature. The associations were risk-decreasing in the present study whereas they were risk-increasing in previous reports. All these six metabolites also were highly positively correlated in our dataset ( Figure 2 ). The direction of association in our dataset remained consistent after adjusting for additional neurocognitive risk factors in regression models 2 and 3, though they became less statistically significant. One of these metabolites, 7-methylguanine was also associated with improved cognitive function (change in DSS test) in ARIC Blacks (P-values = .03 and .04 in APOE ε4 carriers and non-carriers, respectively). The inconsistencies between our findings and prior literature could result from different neurocognitive phenotypes evaluated across studies, differences in population characteristics such as age and genetic architecture, or other lifestyle and environmental factors that could not be adequately accounted for in the models. 30 Such differences between populations may also explain the overall low generalization in the ARIC population (Table S6 ). Further investigation of these metabolites in additional data collected in Hispanics/Latinos, and across diverse populations, is needed to clarify the role of these metabolites in neurocognitive health. A single metabolite, quinolinate, was associated with both MCI and cognitive change in our analysis. Quinolinate is part of the kynurenine pathway of tryptophan catabolism, involved in response to inflammation and infection. The kynurenine pathway is increasingly recognized as contributing to cognitive function. 31, 32 Higher concentrations of both quinolinate and kynurenine were associated with improved cognitive change in our study, while previous studies primarily reported these two metabolites as associated with neuronal damage. 32 In generalization analysis in European Americans from ARIC, quinolinate was nominally associated (P-value = .05) with worse 6-year cognitive performance in the DSS test in APOE ε4 carriers. A possible explanation for these contrasting results could be the recognition that quinolinate is a double-edged sword, acting as both an essential metabolite in the kynurenine pathway of tryptophan catabolism and a potent neurotoxin with a pro-apoptotic effect on some cell types. 33 In fact, kynurenine pathway metabolites have recently been proposed as a potential treatment or therapeutic biomarker for neuropsychiatric disorders. 31 Interpretation of these contrasting results is further complicated because metabolites measured in peripheral blood, as done in this study, may show a different effect compared to other studies that measure the brain metabolites. 31 Future work is needed to elucidate their complex association and therapeutic potential for neurocognitive conditions. We identified six novel associations of metabolites with MCI that were not previously implicated with neurocognition. Aminoisobutyrate, a risk decreasing factor, is a nucleotide in the pyrimidine metabolism pathway produced by skeletal muscle during physical activity. This metabolite was suggested to decrease the risk for metabolic syndrome and its cardiovascular complications, which are known risk factors for dementia. 34 The present study adds to the growing body of research that uses fasting blood metabolites to predict neurocognitive aging outcomes. We provide an in-depth analysis of the associations of a broad panel Alzheimer's disease facts and figures Alzheimer's disease facts and figures APOE alleles ' association with cognitive function differs across Hispanic /Latino groups and genetic ancestry in the study of Latinos-investigation of neurocognitive aging ( HCHS / SOL ) The natural history of cognitive decline in Alzheimer's disease Frequency and course of mild cognitive impairment in a multiethnic community Mild cognitive impairment Metabolomics for the masses: the future of metabolomics in a personalized world Metabolomics in the development and progression of dementia: a systematic review Association of branchedchain amino acids and other circulating metabolites with risk of incident dementia and Alzheimer's disease: a prospective study in eight cohorts Association of amine biomarkers with incident dementia and Alzheimer's disease in the Framingham Study Identification of altered metabolic pathways in plasma and CSF in mild cognitive impairment and Alzheimer's disease using metabolomics Metabolomics and cognition in African American adults in midlife: the atherosclerosis risk in communities study Prospective associations of plasma phospholipids and mild cognitive impairment/dementia among African Americans in the ARIC Neurocognitive Study A research framework for cognitive aging and Alzheimer's disease among diverse US Latinos: design and implementation of the Hispanic Community Health Study/Study of Latinos-Investigation of Neurocognitive Aging (SOL-INCA) Sample design and cohort selection in the Hispanic Community Health Study/Study of Latinos Design and implementation of the Hispanic Community Health Study/Study of Latinos Six-Item Screener to Identify Cognitive Impairment among Potential Subjects for Clinical Perkins A new verbal learning and memory test for English-and Spanish-speaking older people Neuropsychological Assessment HCHS/SOL Manual 9 Neurocognitive Function The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Prevalence and correlates of mild cognitive impairment among diverse Hispanics/Latinos: study of latinos-investigation of neurocognitive aging results A genome-wide association study discovers 46 loci of the human metabolome in the Hispanic Community Health Study/Study of Latinos Tests for regression models fitted to survey data Regression shrinkage and selection via the lasso Altered bile acid profile in mild cognitive impairment and Alzheimer's disease: relationship to neuroimaging and CSF biomarkers Cholesterol and dementia: a long and complicated relationship Involvement of lipids in Alzheimer's disease pathology and potential therapies Metabolite profiling for the identification of altered metabolic pathways in Alzheimer's disease Integration of epidemiologic, pharmacologic, genetic and gut microbiome data in a drug-metabolite atlas The kynurenine pathway: a finger in every pie The kynurenine pathway and the brain: challenges, controversies and promises Quinolinate as a marker for kynurenine metabolite formation and the unresolved question of NAD+ synthesis during inflammation and infection Beta-aminoisobutyric acid as a novel regulator of carbohydrate and lipid metabolism Niacin in the central nervous system: an update of biological aspects and clinical applications Altered bile acid profile associates with cognitive impairment in Alzheimer's disease-An emerging role for gut microbiome Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's disease biomarker discovery cohort Novel serum metabolites associate with cognition phenotypes among Bogalusa Heart Study participants CSF metabolites associate with CSF tau and improve prediction of Alzheimer's disease status Are kynurenines accomplices or principal villains in dementia? Maintenance of kynurenine metabolism Capillary electrophoresis-mass spectrometry-based metabolome analysis of serum and saliva from neurodegenerative dementia patients γ-Glutamylamines and neurodegenerative diseases Carnosine as an effective neuroprotector in brain pathology and potential neuromodulator in normal conditions Cognitiveenhancing activity of thymol and carvacrol in two rat models of dementia Additional supporting information may be found in the online version of the article at the publisher's website.